- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Tahir Amin: Lessons Learned from Allergan's Patent Transfer
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses lessons learned from Allergan's transfer of patents to a sovereign tribe.
Transcript:
What have we learned from Allergan’s transfer of patents to a sovereign tribe about patents in the United States?
Thankfully we’ve learned that the courts struck it down. They saw it for what it was, there was a decision in Texas where the judge called it for what it was, then the PTAB also said no, these [inter partes review, IPRs] will go ahead. Thankfully, we saw sense that a maneuver by Allergan to actually avoid its patents from being challenged was avoided.
Unfortunately, I think that’s just the tip of the iceberg. Companies have a whole toolbox of strategies and tricks that they use, and unfortunately, in a way they’ve undermined what the patent system was originally intended for. Now they use it for a defensive and business strategy; it’s no longer about a strategy for invention and progress.
Instead, it’s just as much about how to keep my competitors off the marketplace, how can I build my fences, how can I keep my profits at the highest, when, really, we should be allowing progress to happen in a different way. For anyone who is a free-market person, the way the patent system works today is antithetical to a free market.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Top 5 Most-Read Legal Articles of 2024
December 23rd 2024The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and addressing challenges like litigation, regulatory hurdles, and patent disputes that shape the competitive landscape of affordable biologics.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
